Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Drug conjugate takes aim at Hard-to-Treat prostate cancer

NCT ID NCT07258407

Recruiting now Disease control Sponsor: T.O.A.D. Oncology SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (PSMA). The trial will enroll 180 participants to find the safest dose and schedule, and to see if the drug can slow the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TD001 (an antibody-drug conjugate that targets PSMA on prostate cancer cells)

What this could lead to

If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.

What could go wrong

This is an early phase 1/2 trial, so the main goals are safety and finding the right dose. It is too soon to know if TD001 will shrink tumors or improve survival, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATIC CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Paris Saint Joseph

    RECRUITING

    Paris, 75014, France

  • Institut Bergonié

    RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Vall d'Hebron Institute of Oncology

    RECRUITING

    Barcelona, 08035, Spain

  • Yale University, Yale Cancer Center

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06520, United States